Rite Aid Corporation Confirms Prior Rejection of Non-Binding, Off-Market Proposal from Spear Point Capital Management

Rite Aid Corporation (NYSE: RAD) confirmed that it previously rejected a non-binding, off-market proposal from Spear Point Capital Management (“Spear Point”) to acquire all of the outstanding shares of the Company’s common stock. The Company and its Board of Directors reviewed the proposal with the assistance of its financial and legal advisors, and the Board concluded that the proposal was not credible and did not warrant further exploration.

In making its determination, the Board considered, among other defects, that the Spear Point proposal provided no evidence of financing, required multiple months of exclusivity and then called for Rite Aid to spend months soliciting competing offers. In addition, Spear Point’s proposal was conditioned on none of the Company’s debt becoming due and payable upon a change in control, which contradicts the terms of nearly all of Rite Aid’s debt instruments. Furthermore, Spear Point has no track record of acquiring public companies the size and complexity of Rite Aid.

The Company remains focused on executing its growth strategy through continued leadership as a full-service pharmacy company, and will, as always, be responsive to credible proposals that will enhance stockholder value.

About Rite Aid Corporation

Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to Americans 365 days a year. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,400 retail pharmacy locations across 17 states. Through Elixir, we provide pharmacy benefits and services to millions of members nationwide. For more information, visit www.riteaid.com.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.